The FDA has approved rivaroxaban to reduce the risk of major cardiovascular events including stroke, myocardial infarction and cardiovascular death for people with chronic peripheral or coronary artery disease (PAD/CAD).

A study presented at TCT 2018 questioned the benefits of “drip-and-ship” for elderly patients with ST-segment elevation myocardial infarction (STEMI), finding patients in their 80s or older who were transferred with fibrinolytic therapy for PCI had an eight-fold risk of hemorrhagic stroke but no survival advantage.

Antiepileptic drugs, regardless of brand or type, increase risk of stroke in seniors diagnosed with Alzheimer’s disease, according to research published in the Journal of the American Heart Association.

Fewer than one-third of Chinese patients with acute coronary syndromes (ACS) receive guidance to participate in cardiac rehabilitation, according to research presented Oct. 11 at the Great Wall International Congress of Cardiology.

Preliminary results from the RETAKO trial, a study of takotsubo syndrome (TTS) in the Spanish population, have identified cardiogenic shock as an independent, strong predictor of mortality and complexities in TTS patients—a demographic that’s already at considerable risk for complications.

People with unrecognized myocardial infarction carry a lower short-term risk of death but an equal 10-year risk of mortality compared to those with clinically diagnosed heart attacks, according to an analysis of the ICELAND MI study published in JAMA Cardiology.

Three men with type 2 diabetes used intermittent fasting to lose weight, lower their blood sugar levels and reverse their dependence on insulin treatment, according to a case study report published in The BMJ.

Socioeconomic factors—namely a mother’s insurance status and level of education—weigh heavily on Hispanic infants’ chances of surviving critical congenital heart disease (CHD) in their first year of life, a study out of the University of California, San Francisco suggests.